William Hilson

Background

About William Hilson

William brings over three decades of operational and capital markets experience in the pharmaceutical and health care sectors. He was the founding chief financial officer and subsequently chief commercial officer of Cronos Group Inc.(CRON: NASDAQ), the first cannabis company to list on a major U.S. securities exchange. Founded in 2016, Cronos closed a C$2.4 billion strategic investment from Altria Group in 2019. Before this, Mr. Hilson spent over 15 years in executive roles with multinational pharmaceutical companies. As the CFO of Serono Canada Inc. and later the CFO of EMD Inc.(div. of Merck KGaA), his responsibilities included financial operations, strategy, performance management, capital markets, international tax, debt, and equity financing. Mr. Hilson was also involved in many M&A and licensing deals in the pharmaceutical industry. He is a chartered public accountant (CPA) and holds an audit chair certificate from McMaster University. He has an MSc in clinical biochemistry from the University of Toronto and an Honors BSc in genetics from the University of Western Ontario. Mr. Hilson completed his clinical research in neuroscience at the Hospital for Sick Children in Toronto